Document Detail


Lipid and non-lipid effects of statins.
MedLine Citation:
PMID:  16596807     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Long- and short-term trials with the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have demonstrated significant reductions in cardiovascular events in patients with and without history of coronary heart disease. Statins are well-established low-density lipoprotein (LDL)-lowering agents, but their clinical benefit is believed to result from a number of lipid and non-lipid effects beyond LDL lowering, including a rise in plasma high-density lipoprotein levels. Beyond improving the lipid profile, statins have additional non-lipid effects including benefit on endothelial function, inflammatory mediators, intima-media thickening, prothombotic factors that ultimately result in plaque stabilization. These effects arise through the inhibition of several mevalonate-derived metabolites other than cholesterol itself, which are involved in the control of different cellular functions. Although statins represent the gold standard in the prevention and treatment of coronary heart disease, combination therapy with other lipid-lowering drugs, as well as novel therapeutic indications, may increase their therapeutic potential.
Authors:
R Paoletti; C Bolego; A Cignarella
Related Documents :
6740187 - The bucharest multifactorial prevention trial of coronary heart disease--ten year follo...
15150487 - Statins and secondary prevention of coronary heart disease.
6331147 - Cardiovascular features of homozygous familial hypercholesterolemia: analysis of 16 pat...
15757077 - Effect of preexisting statin use on expression of c-reactive protein, adhesion molecule...
20425747 - Multiple embolisations in rheumatic heart disease: a case report.
421547 - The advantages of open mitral commissurotomy for mitral stenosis.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Handbook of experimental pharmacology     Volume:  -     ISSN:  0171-2004     ISO Abbreviation:  Handb Exp Pharmacol     Publication Date:  2005  
Date Detail:
Created Date:  2006-04-06     Completed Date:  2006-04-19     Revised Date:  2007-05-15    
Medline Journal Info:
Nlm Unique ID:  7902231     Medline TA:  Handb Exp Pharmacol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  365-88     Citation Subset:  IM    
Affiliation:
Department of Pharmacological Sciences, University of Milan, Italy. rodolfo.paoletti@unimi.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anticholesteremic Agents / pharmacology*
Atherosclerosis / drug therapy*
C-Reactive Protein / analysis
Endothelium, Vascular / physiology
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*,  therapeutic use
Lipoprotein(a) / blood
Lipoproteins, HDL / blood
Lipoproteins, LDL / blood,  metabolism
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Lipoprotein(a); 0/Lipoproteins, HDL; 0/Lipoproteins, LDL; 0/oxidized low density lipoprotein; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Alcohol.
Next Document:  Fibrates.